Global Oncology Societies Unify Framework for Liver Cancer Trials

Four major liver and oncology societies have joined forces to create a unified framework for hepatocellular carcinoma (HCC) clinical trials. The aim is to standardise trial design and improve consistency across research efforts. This collaboration seeks to address long-standing challenges in HCC treatment studies. The new framework tackles key issues in survival analysis, particularly non-proportional hazards in statistical models. It provides clear guidance on selecting the right methods to interpret trial outcomes accurately. A core dataset of essential variables will now be collected uniformly in phase II and III trials to ensure high-quality data and easier comparisons between studies.

Tumor biopsy will be mandatory before enrolling patients in any HCC trial. This requirement will help deepen molecular understanding and support the development of biomarker-driven treatments. The consensus also pushes for more randomised controlled trials to test the combination of systemic therapies with curative treatments in early and intermediate-stage HCC.

Adaptive trial designs are encouraged to speed up the validation of biomarkers and the introduction of new agents. Patient-reported outcomes and quality of life assessments will now be standard endpoints in all trial phases. Additionally, a structured approach has been introduced to measure clinical benefit, using validated surrogate endpoints alongside early survival signals.

The agreement highlights the urgent need for predictive and prognostic biomarkers. It also stresses the importance of validating surrogate markers for survival to improve trial efficiency. This framework aims to reduce variability in trial design and methodology. It provides researchers with clear tools to improve data quality and accelerate progress in HCC treatment. The societies hope the new standards will lead to more effective and consistent clinical trials.